Physician profile
James V Pellicane
NPI 1093704454
$1,667.21
in general payments reported to CMS, 2019-2025
14 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.44 · 2020: $182 · 2021: $14.93 · 2022: $371 · 2023: $293 · 2024: $228 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $669.61 | 2022-2025 | Hemoblast Bellows |
| Axogen | $213.51 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Nerve Protector |
| Elucent Medical | $169.98 | 2020 | |
| Molli Surgical (US) INC | $125.78 | 2023 | |
| Endomagnetics LTD | $124.90 | 2019-2023 | Magseed, Magtrace |
| Kub Technologies INC. | $99.37 | 2022 | |
| Impedimed, INC. | $49.63 | 2025 | |
| Mentor Worldwide LLC | $49.28 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $46.00 | 2022-2023 | Keytruda, Lynparza |
| Becton, Dickinson and Company | $32.30 | 2025 | Arista |
| Myriad Genetic Laboratories, INC. | $31.00 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $20.60 | 2022 | |
| Motiva USA, LLC | $20.52 | 2025 | |
| Integra Lifesciences Corporation | $14.73 | 2024 | Integra, Surgimend, Integra Dermal Regeneration Template |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pellicane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.